Taurine and Biological Age: Part One: The Hypothesis

Abstract

In June 2023, Science published a paper proposing that taurine deficiency is not a consequence of ageing but one of its drivers. It is the reason taurine moved from the energy-drink aisle to the longevity aisle, and it deserves to be read on its own terms before anyone reads the objections.

This is the first of four parts, one per publication. Part Two covers the human study that failed to reproduce its central premise. Part Three covers a reframing that may reconcile them. Part Four covers a trial that completed while the argument was running.

We should say at the outset that taurine is in one of our own products, and that this series ends somewhere uncomfortable for us. This part is about why the hypothesis was taken seriously in the first place, which it was, and by people who were right to.

1.The Question Behind the Paper

Blood chemistry changes with age. Dozens of metabolites, hormones and micronutrients shift, and almost all of that shifting is assumed to be downstream — the body ages, and the blood reflects it.

Parminder Singh, Vijay Yadav and their colleagues at Columbia asked the inverted question. If a molecule in blood were a driver of ageing rather than a passenger, then restoring its concentration to youthful levels should slow ageing. That is a testable proposition, and taurine — a semi-essential amino acid that the body makes and the diet supplies — was their candidate.

The structure of the paper follows the logic exactly: establish that taurine declines, restore it, and see what happens, in as many species as could be managed.

2.The Decline

The first claim is the one everything else rests on, and it is stated in strong terms.

In monkeys, taurine concentrations in 15-year-old animals were reported as 85 per cent lower than in 5-year-olds. In humans, taurine in elderly individuals was reported as more than 80 per cent lower than in the serum of younger individuals.

Eighty per cent is not a subtle drift. If a molecule essential to cellular function fell by four-fifths across a lifespan, that would be one of the largest age-related changes in human blood chemistry, and it would demand explanation regardless of whether supplementation did anything.

Hold that number. Part Two is about two independent groups looking for it and not finding it.

3.The Restoration

Middle-aged mice were fed taurine daily until the end of life. Median lifespan increased by 10 to 12 per cent, and life expectancy at 28 months by roughly 18 to 25 per cent, in both sexes.

Lifespan alone would be a thin result — an animal can be kept alive without being kept well — so the team measured health span too, and reported improved function of bone, muscle and pancreas in taurine-fed middle-aged mice.

The mechanistic sweep is what made the paper land. Taurine reduced cellular senescence, suppressed the adverse consequences of telomerase deficiency, decreased DNA damage, improved mitochondrial function and attenuated inflammation. In the authors' framing it touched every established hallmark of ageing.

Not everything worked. Taurine did not affect the replicative lifespan of yeast, while it did increase lifespan in worms. That is a useful detail: the effect required a multicellular organism, which is a constraint rather than a failure, and the authors report it.

4.The Monkeys

Aged rhesus monkeys, 15 years old plus or minus 1.5 — roughly equivalent to humans of 45 to 50 — received 250 mg per kilogram of body weight daily for six months, or a control solution.

Three hours after feeding, serum taurine in supplemented monkeys was about twice that of controls, 65.4 nanograms per millilitre against 35.1. Health measures improved across several domains.

The dose is worth converting, because it rarely is. Two hundred and fifty milligrams per kilogram, for a 70-kilogram adult, is 17.5 grams a day. Interspecies scaling is not a simple multiplication, but the order of magnitude is the point: this is a pharmacological intervention, not a dietary one.

5.The Human Data, and What Kind It Is

For humans the paper does something different, and the difference is easy to miss because it appears in the same list of findings.

The team analysed circulating taurine-pathway metabolites — taurine, hypotaurine and N-acetyltaurine — against more than 50 clinical risk factors in 11,966 participants of the EPIC-Norfolk study. Higher blood taurine and hypotaurine were associated with lower body mass index, lower waist-to-hip ratio and less abdominal obesity. Lower concentrations were associated with hypertension, inflammation and prevalence of type 2 diabetes.

Separately, a bout of exercise increased circulating taurine metabolites, which the authors suggest might partly underlie the anti-ageing effects of exercise.

These are correlations in a cohort. No human took taurine in this paper. The lifespan evidence is in worms and mice, the health-span evidence in mice and monkeys, and the human evidence is an association study — a fact the authors state plainly, noting that testing whether taurine deficiency drives ageing in humans would require long-term, well-controlled supplementation trials.

6.What Makes It Good Work

It is worth being explicit about this, because the parts that follow are critical and criticism reads as dismissal when the original is not given its due.

The paper tests one hypothesis across five species. It measures the proposed mechanism rather than inferring it. It reports the species where the effect failed. It converts its own animal doses. And it says, in its own conclusions, exactly what would be needed to establish the claim in humans — which is not what the paper itself did.

The distance between what a paper claims and what a market does with it is not usually the paper's fault. Within eighteen months, taurine was being sold on the strength of a mouse lifespan curve and a cohort correlation.

Editorial Comment

Taurine is in Boost at 500 mg. We make no claim that it slows ageing, and none is authorised in the European Union — taurine has no approved health claim of any kind.

This part exists to state the strongest version of the case before we take it apart. A reader who only encountered our objections would end up with a distorted picture: this is serious work, published in the most demanding venue in science, and the hypothesis it proposed was worth the attention it received.

What happened next is the subject of Part Two, where a Canadian group looked for the 80 per cent decline in 137 men aged 20 to 93 and reported that circulating taurine showed no association with age at all.